Condition: RAS Mutation · NF1 Mutation · RAF Mutation · Sponsor: Pasithea Therapeutics Corp.
The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: * How well participants are able tolerate different doses of PAS-004, and * What side effects PAS-004 might have. Study participants will have regular visits to the study doctor and be asked to have tests and exams done to check on their health and safety. Everyone participating in the study will take PAS-004 by mouth as a single dose, followed by one week observation, then once a day during the study, in 28-day cycles. Participants will continue on daily PAS-004 for up to 2 years, or until: * They decide to withdraw from the study, or * They experience unacceptable side effects, or * Their disease progresses, or another illness interferes with taking the study drug, or * The sponsors stops the study.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| NEXT Oncology | Austin, Texas, United States | Active Not Recruiting |
| NEXT Oncology | Irving, Texas, United States | Active Not Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Active Not Recruiting |
| NEXT Oncology | Fairfax, Virginia, United States | Active Not Recruiting |
| MBAL Sveta Sofia | Sofia, Bulgaria | Recruiting |
| Institute of Oncology Bucharest Prof. Dr. Alexandru Trestioreanu | Bucharest, Romania | Recruiting |
| Institute of Oncology Prof. Dr. Ion Chiricuta | Cluj-Napoca, Romania | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06299839